Receptor-targeted nanoparticles for in vivo imaging of breast cancer

Lily Yang, Xiang Hong Peng, Y. Andrew Wang, Xiaoxia Wang, Zehong Cao, Chunchun Ni, Prasanthi Karna, Xinjian Zhang, William C. Wood, Xiaoh Gao, Shuming Nie, Hui Mao

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Cell-surface receptor-targeted magnetic iron oxide nanoparticles provide molecular magnetic resonance imaging contrast agents for improving specificity of the detection of human cancer. Experimental Design:The present study reports the development of a novel targeted iron oxide nanoparticle using a recombinant peptide containing the amino-terminal fragment of urokinasetype plasminogen activator (uPA) conjugated tomagnetic ironoxide nanoparticles amino-terminal fragment conjugated-iron oxide (ATF-IO).This nanoparticle targets uPA receptor,which is overexpressedinbreast cancer tissues. Results: ATF-IO nanoparticles are able to specifically bind to and be internalized by uPA receptor - expressing tumor cells. Systemic delivery of ATF-IO nanoparticles into mice bearing s.c. and i.p. mammary tumors leads to the accumulation of the particles in tumors, generating a strongmagnetic resonance imaging contrast detectable by a clinicalmagnetic resonance imaging scanner at a field strength of 3 tesla.Target specificity of ATF-IOnanoparticles showed by in vivo magnetic resonance imaging is further confirmed by near-IR fluorescence imaging of the mammary tumors using near-IR dye-labeled amino-terminal fragment peptides conjugated to iron oxide nanoparticles. Furthermore, mice administered ATF-IO nanoparticles exhibit lower uptake of the particles in the liver and spleen compared with those receiving nontargeted iron oxide nanoparticles.

Original languageEnglish (US)
Pages (from-to)4722-4732
Number of pages11
JournalClinical Cancer Research
Volume15
Issue number14
DOIs
StatePublished - Jul 15 2009
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Receptor-targeted nanoparticles for in vivo imaging of breast cancer'. Together they form a unique fingerprint.

Cite this